Forma Therapeutics Holdings, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY21 | FY20 | FY19 | |
|---|---|---|---|
| Revenue | $0 | $0 | $72.0M |
| Operating income | −$174.0M | −$32.2M | $34.2M |
| Net income | −$173.0M | $11.2M | $35.6M |
| Total assets | $561.1M | $681.0M | $183.0M |
| Total liabilities | $62.7M | $32.7M | $26.7M |
| Equity | $498.4M | $648.2M | $18.2M |
| EPS (diluted) | — | $0.36 | $-21.08 |
| Shares out. | 47.4M | 47.2M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2021- Operating margin
- —
- Net margin
- —
- Return on equity
- −34.7%
- Return on assets
- −30.8%
- Return on capital (ROCE)
- −33.1%
- Liabilities / assets
- 11.2%
- Debt / equity
- 0.13×
- Book value / share
- $10.52
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- −1640.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2021- Altman Z″ (distress)
- 10.20safe
- Accruals / assets
- −4.1%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-02-06A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
- Phase 2Recruitingreadout ~2027-09-20A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- Phase 2Recruitingreadout ~2028-02-23A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lesser Brian AndrewOfficer — SVP, Commercial Officer | Oct 14, 2022 | U | 10,000 | — |
| Potts JeannetteOfficer — See Remarks | Oct 14, 2022 | U | 3,400 | — |
| Fanucci MarshaDirector | Oct 14, 2022 | U | 52,532 | — |
| Frederick Wayne A.I.Director | Oct 14, 2022 | U | 7,250 | — |
| Lee Frank D.Officer — President and CEO | Oct 14, 2022 | U | 201,436 | — |
| Molina Arturo MdDirector | Oct 14, 2022 | U | 10,000 | — |
| Melian AgustinOfficer — EVP, Research & Development | Oct 14, 2022 | U | 79,000 | — |
| Bishop John EOfficer — SVP, Chief Technology Officer | Oct 14, 2022 | U | 47,950 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 14, 2022
- Entered a material agreement · Other material eventSep 1, 2022
- Results of operationsAug 5, 2022
- Director / officer changeJul 25, 2022
- Shareholder voteJun 9, 2022
- Regulation FD disclosure · Other material eventMay 26, 2022
- Results of operationsMay 6, 2022
- Results of operations · Other material eventMar 1, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2023
- 15-12GOct 24, 2022
- EFFECTOct 17, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022
- 4FORM 4 SUBMISSIONOct 14, 2022